Novo Nordisk Ends Hims & Hers Over Wegovy Compounding

Novo Nordisk has abruptly ended its partnership with telehealth company Hims & Hers Health, only weeks after it began, due to concerns that Hims & Hers was selling illegal, mass-produced compounded versions of the obesity drug Wegovy using foreign-sourced active ingredients from China. Novo Nordisk accused Hims & Hers of deceptive marketing and falsely claiming personalized treatments while allegedly violating drug compounding laws. As a result, Hims & Hers was removed from Novo Nordisk’s direct access program for Wegovy. The decision followed the resolution of a national Wegovy shortage and comes amid broader scrutiny of compounded drug sales and regulatory compliance in the weight-loss market. Hims & Hers shares plummeted by over 20% after the announcement. Novo Nordisk will continue working with telehealth companies that provide only authentic, FDA-approved Wegovy.